Editas Medicine, Inc. Common Stock EDIT
Analyst Ratings
- Consensus
- Buy — 3 Buy · 0 Hold · 0 Sell (3 analysts)
- Avg. Price Target
- $6.00 (+122.2% upside)
Key Stats
- Today's Range
- $2.68 – $2.83
- 50-Day Range
- $2.52 – $3.52
- 52-Week Range
- $1.66 – $4.54
- Volume
- 17.03 million shs
- Average Volume
- 2.98 million shs
- Market Cap
- $414.67 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 3.94
- Price / Sales
- 8.82
Short Interest
- Short Interest
- 4.06%
- Days to Cover
- 5.54
Financials (TTM)
- Revenue
- $47.01 million
- Net Income
- $-73,949,000
- Net Margin
- -157.32%
- Return on Equity
- -70.24%
- Debt-to-Equity
- —
About Editas Medicine, Inc. Common Stock
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Related Stocks
Compare head-to-head: EDIT vs AMGN·EDIT vs MRNA·EDIT vs HALO·EDIT vs TWST
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.